Semaglutide for Chronic Kidney Disease

How Semaglutide Helps with Chronic Kidney Disease

Semaglutide mimics the GLP-1 hormone to reduce appetite and slow stomach emptying, leading to significant weight loss. For patients with chronic kidney disease, this weight loss translates to meaningful improvements in condition-specific outcomes.

The FLOW trial showed semaglutide reduces kidney disease progression by 24% in patients with type 2 diabetes and chronic kidney disease. The STEP clinical trial program demonstrated that semaglutide 2.4mg weekly produces an average weight loss of 15% of body weight over 68 weeks, with additional benefits for metabolic health markers.

Clinical Evidence for Chronic Kidney Disease

Chronic Kidney Disease affects approximately 37 million American adults (15% of the population). Research shows that GLP-1 medications like semaglutide address both the weight component and the underlying metabolic dysfunction associated with chronic kidney disease. Patients with this condition often see compounding benefits from weight loss, including improved energy, mobility, and overall quality of life.

Semaglutide Dosing for Chronic Kidney Disease

Semaglutide is taken as a once-weekly subcutaneous injection. The standard titration starts at 0.25mg and gradually increases to the maintenance dose of 2.4mg over 16-20 weeks. Dosing is the same regardless of the indication — your provider will monitor your response and adjust timing as needed.

Cost of Semaglutide for Chronic Kidney Disease

Compounded semaglutide costs $149-399/month through telehealth providers. Brand-name Wegovy costs $1,300+/month without insurance. Many patients with chronic kidney disease have associated comorbidities that improve insurance coverage chances.